Successful treatment of cold agglutinin disease with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus

被引：17

作者：

Kotani, T. ^{[1
]}

Takeuchi, T. ^{[1
]}

Kawasaki, Y. ^{[1
]}

Hirano, S. ^{[1
]}

Tabushi, Y. ^{[1
]}

Kagitani, M. ^{[1
]}

Makino, S. ^{[1
]}

Hanafusa, T. ^{[1
]}

机构：

[1] Osaka Med Coll, Dept Internal Med 1, Takatsuki, Osaka 5698686, Japan

来源：

LUPUS | 2006年 / 15卷 / 10期

关键词：

cold agglutinin disease; hemolytic anaemia; rituximab; systemic lupus erythematosus;

D O I：

10.1177/0961203306070983

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cold agglutinin disease (CAD) is a rare cause of anaemia in patients with systemic lupus erythematosus (SLE). CAD is usually refractory to glucocorticosteroid, and other immunosuppressive and/or cytotoxic therapies. We report the case of a 55-years old woman with SLE and CAD that did not respond to high-dose methylprednisolone, cyclosporin A, and double filtration plasma pheresis. Because several recent case reports and studies have indicated promising results of rituximab treatment for CAD and for SLE, rituximab was given weekly at 375 mg/m(2) in two doses. The rituximab was well tolerated, and there were no adverse effects. The hemolysis and SLE improved markedly, and the patient remained disease free eight months later. This is the first report of successful rituximab treatment of CAD in a patient with SLE. We conclude that rituximab is worth trying in such patients if they fail to respond to conventional treatment.

引用

页码：683 / 685

页数：3

共 10 条

[1] Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease [J].

Berentsen, S ;

Tjonnfjord, GE ;

Brudevold, R ;

Gjertsen, BT ;

Langholm, R ;

Lokkevik, E ;

Sorbo, JH ;

Ulvestad, E .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (01) :79-83

[2] An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab [J].

Boye, J ;

Elter, T ;

Engert, A .

ANNALS OF ONCOLOGY, 2003, 14 (04) :520-535

[3] HOW B-CELLS AND T-CELLS TALK TO EACH OTHER [J].

CLARK, EA ;

LEDBETTER, JA .

NATURE, 1994, 367 (6462) :425-428

[4] Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment [J].

Giannouli, S ;

Voulgarelis, M ;

Ziakas, PD ;

Tzioufas, AG .

ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (02) :144-148

[5] B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients [J].

Leandro, MJ ;

Cambridge, G ;

Edwards, JC ;

Ehrenstein, MR ;

Isenberg, DA .

RHEUMATOLOGY, 2005, 44 (12) :1542-1545

[6] B cell depletion as a novel treatment for systemic lupus erythematosus - A phase I/II dose-escalation trial of rituximab [J].

Looney, RJ ;

Anolik, JH ;

Campbell, D ;

Felgar, RE ;

Young, F ;

Arend, LJ ;

Sloand, JA ;

Rosenblatt, J ;

Sanz, I .

ARTHRITIS AND RHEUMATISM, 2004, 50 (08) :2580-2589

[7] Pathogenesis of systemic lupus erythematosus [J].

Mok, CC ;

Lau, CS .

JOURNAL OF CLINICAL PATHOLOGY, 2003, 56 (07) :481-490

[8]

PARKER DC, 1993, ANNU REV IMMUNOL, V11, P331, DOI 10.1146/annurev.immunol.11.1.331

[9]

PIROFSKY B, 1975, CLIN HAEMATOL, V4, P167

[10] Rituximab in a case of cold agglutinin disease [J].

Zaja, F ;

Russo, D ;

Fuga, G ;

Michelutti, T ;

Sperotto, A ;

Fanin, R ;

Baccarani, M .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (01) :232-233

← 1 →